DOCSLIB.ORG

Stopping Cocaine Before It Gets to the Brain: New Frontiers in Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stopping Cocaine Before It Gets to the Brain: New Frontiers in Treatment Stopping cocaine before it gets to the brain: new frontiers in treatment CELAC Symposium “Progress and Challenges in Scientific Research on Treatments, Pharmacological Strategies and Vaccines against Drug Addiction” 1 Marilyn E. Carroll 2 2 3 Collaborators: Stephen Brimijoin , Yang Gao , Robin Parks , 1 1 Natalie E. Zlebnik , Justin J. Anker 1Department of Psychiatry, University of Minnesota, Minneapolis, MN 2Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 3Regenerative Medicine Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada NIDA Tested Medications for Treatment of Cocaine Dependence Amantadine Disulfiram Lofexidine Propanolol Lys-dex Divalproex Lobeline Reboxetine amphetamine Dronabinol LY544344 Risperidone Aripriprazole* Fluoxetine* Mecamylamine RTI compounds Atomoxetine Gabapentin Memantine Selegiline Baclofen GBR12909 Methamphetamine Sertraline Buprenorphine GCP44352 Methylphenidate Tiagabine Bup/naloxone Gammavinyl GABA Methadone Topiramate Bupropion Hydromorphone Modafinil Vigagatrin Buspirone LAAM N-acetyl-aspartate Venlafaxine Clonidine L-Dopa/Carbidopa Naltrexone x 2 Yohimbine DHEA L-tryptophan Olanzapine … and More Desipramine Pergolide d-Amphetamine Progesterone Dextrometorphan 3 studies of cocaine hydrolase (CocH) treatment to acutely block: 1. Cocaine self-administration (progressive ratio) 2. Cocaine escalation 3. Cocaine reinstatement 3 studies of CocH viral vector (VEC) treatment to chronically block: 1. Cocaine reinstatement 2. Cocaine-induced locomotor sensitization with cocaine vaccine (VAC) 3. Cocaine self-administration (VEC + VAC) 3 studies of cocaine hydrolase (CocH) treatment to acutely block: 1. Cocaine self-administration (progressive ratio) 2. Cocaine escalation 3. Cocaine reinstatement 3 studies of CocH viral vector (VEC) treatment to chronically block: 1. Cocaine reinstatement 2. Cocaine-induced locomotor sensitization with cocaine vaccine (VAC) 3. Cocaine self-administration (VEC + VAC) BChE - cocaine hydrolase (CocH) - genetically engineered from human BChE A199S/F227A/S287G/A328W/Y332G 10000 F227AS/S287G/A328W/Y332A CocH 1000 cat A199S/S287G/A328W/Y332G 100 cocaine k cocaine A328W/Y332A 10 wild type BChE 1 1 2 3 4 5 (2002) (2003) (2004) (2008) Successive Mutation Generations Molecular interception by enzyme (“Pac-man model”) CocH drastically accelerates cocaine metabolism in rats unprotected subject brain 2500 blood 2000 control rats cocaine 1500 enzyme- 1000 enzyme-treated subject pretreated 500 plasma cocaine brain 0 0 30 60 90 120 blood cocaine Gao et al, Chemico-Biol. Interact. 2010 Brimijoin et al. Neuropsychopharmacol 33: 2715-2725, 2008 CocH rescues rats from cocaine-induced seizures Brimijoin et al. Neuropsychopharmacol 33: 2715-2725, 2008 Locomotor activity apparatus CocH prevents cocaine-induced locomotor activity in mice 70 60 50 40 No BChE Wildtype 30 CocH No Cocaine 20 Beam Crossings Beam 10 0 0 10 20 30 40 50 60 70 Time (min) Brimijoin et al. Neuropsychopharmacol 33: 2715-2725, 2008 Cocaine hydrolase treatment requires enzyme activity to suppress cocaine-stimulation in mice Cholinesterase inhibitor, iso-OMPA, blocked enzyme activity inhibitor restores stimulation inhibitor alone - no effect in presence of enzyme ** ** 500 ** 400 ** ** ** Distance 300 traveled 200 distance distance traveled 100 0 saline CocH CocH + control iso-OMPA iso-OMPA cocaine Carroll et al., 2012 IV drug self-administration apparatus Phases of Drug Abuse Process = 3 studies Acquisition Short vs. Long Access Extinction Reinstatement Drugs Responding Sal Operant Responding Operant Short Access Time (~ 2 - 3 months) Modified from de Vries (1998) and Ahmed and Koob (1998) Cocaine self-administration during short access (2 h) under a progressive-ratio (PR) schedule to assess motivation ** 15 b ** ** CocH enzyme (vs saline) ++ reduced PR performance ++ 12 ++ for 1 session 9 6 3 Mean Mean Infusions (±SEM) 0 0 (Sal) 2 1 4 Albu-CocH Dose (mg/kg) B D A B D A B D A Before, During, After CocH Carroll et al. Psychopharmacology, 2011 Escalation of cocaine self-administration during long access (6 h) d Saline or enzyme treatment 700 For first 7 days 2 mg/kg CocH 600 Saline # 500 ** # ** CocH enzyme (vs saline) increased 400 cocaine infusions for first 4 (of 7) days 300 # # 200 Mean Mean (±SEM) Infusions 100 0 0 3 6 9 12 15 18 21 Days Carroll et al. Psychopharmacology, 2011 Reinstatement (relapse) responses with CocH enzyme no effect on reinst. 4 days after CocH SEM) Responses SEM) CocH acutely ± blocked reinst. Mean ( (E) Enzyme pretreatment (C) cocaine priming injection (S) Saline pretreatment (A) amphetamine priming injection Brimijoin et al. Neuropsychopharmacology 2008 3 studies of cocaine hydrolase (CocH) treatment to acutely block: 1. Cocaine self-administration (progressive ratio) 2. Cocaine escalation 3. Cocaine reinstatement 3 studies of CocH viral vector (VEC) treatment to chronically block: 1. Cocaine reinstatement 2. Cocaine-induced locomotor sensitization with cocaine vaccine (VAC) 3. Cocaine self-administration (VEC + VAC) Adenoviral gene delivery for long-term actions Hydrolase transduction raises cocaine-hydrolase activity in plasma up to 1,000,000-fold 10000 4500 units 1000 100 10 1 .1 CocE activityCocE (mU/ml) .01 0.0045 units .001 1x 3x 5x 10x 5x Control CocE AME359 Year-long generation of CocH with helper-dependent adenoviral vector (hdAD) by gene transfer 10 0 0 hdAD 10 0 10 (mU/ml) 1 first-generation vector 0. 1 injected enzyme cocaine hydrolase activity hydrolase cocaine 0. 0 1 0 10 0 20 0 30 0 40 0 days after injection Ottawa, Mayo Gao and Brimijoin J Pharmacol Exp Ther 330:449-457, 2009 Gene transfer of hydrolase blocks fosB induction in neostriatum in rats given repeated cocaine treatment MW 134 FosB 82 41 32 AME + C S + S E + C S + C CocH 4 3 2 1 0 saline onlysaline AME empty cocaine induction Gao and Brimijoin J Pharmacol Exp Ther 330:449-457, 2009 Cocaine clearance in blood plasma in rats treated 2 weeks earlier with CocH vector or saline controls Plasma cocaine minimal in CocH vector-treated group Plasma cocaine (uM) cocaine Plasma Anker et al., Biol. Psychiatry, 2011 CocH vector reinstatement procedure 1 injection of CocH vector or saline 1 day before extinction P hase ACQ MAINT EXT Reinstatement (8) Protracted Reinstatement (days) (~10) (~10) (14) S C S C S C S A S C S C S C S C S C S C S C S C S A Dose C 0.4 mg/kg, i.v. C (5, 10, 15 ); A (2) C (10) C (10); A (2) (mg/kg, i.p.) Weeks N/A N/A 3 5 6 7 8 12 16 20 24 post vector Blood draws for CocH levels weekly then monthly Anker et al., Biol. Psychiatry, 2011 Maintenance Extinction Males Females Anker et al. Biol. Psychiatry, 2011 Reinstatement after CocH vector (week 3) by cocaine priming dose 15 16 17 18 19 20 21 22 23 24 Days post CocH vector injection Anker et al., Biol. Psychiatry, 2011 Reinstatement responding after CocH vector (weeks 5 - 8) Control > CocH vector Minimal responding on days of saline (S) or no priming injections (1-5) Anker et al., Biol. Psychiatry, 2011 Active lever reinstatement responding # * group differences (0.01, 0.05) Anker et al., Biol. Psychiatry, 2011 Active lever reinstatement responding # * group differences (0.01, 0.05) CocH blood levels (no differences across weeks) SEM) ± Mean ( Mean CocH Vmax (mU/ml)CocH Anker et al., Biol. Psychiatry, 2011 Active lever reinstatement responding Inactive lever responding - control for general # * group differences behavioral suppression no group differences Anker et al., Biol. Psychiatry, 2011 Active lever responding first 3 days after return to operant chamber for monthly reinstatement testing * Day 1 > Days 2 and 3 no group differences Anker et al., Biol. Psychiatry, 2011 Spontaneous locomotor behavior during 3 45 min sessions - - CocH vector vs control (no cocaine administered) no group differences CocH vector did not suppress locomotor activity. Anker et al., Biol. Psychiatry, 2011 3 studies of cocaine hydrolase (CocH) treatment to acutely block: 1. cocaine self-administration (progressive ratio) 2. cocaine escalation 3. cocaine reinstatement 3 studies of CocH viral vector (VEC) treatment to chronically block: 1. cocaine reinstatement 2. cocaine-induced locomotor sensitization with cocaine vaccine (VAC) 3. Cocaine self-administration (VEC + VAC) Enhanced interception with Enzyme & Vaccine brain unprotected subject blood cocaine brain enzyme-treated blood cocaine brain antibody-treated blood cocaine brain enzyme plus antibody blood cocaine Locomotor activity apparatus Each session = Saline - locomotor chamber (45 min) then cocaine (10 mg/kg) - locomotor chamber (45 min) Day 8 Locomotor activity Sensitization Coc > Sal > V+V Day 1 vs 8 Control Yes Yes Yes VAC Yes Yes blocked VEC Yes Yes Yes V + V blocked blocked Carroll et al., 2012 Mean beam breaks over 45 min following cocaine injections across the 8 days of cocaine treatment V + V > VAC, VEC, and Control in reducing locomotor behavior Carroll et al., 2012 Challenge = saline or cocaine injected 15 days after the 8 treatment days Day 24 Locomotor activity Sensitization Coc > Sal < Control Day 1 vs 23 Control Yes Yes VAC Yes Yes blocked VEC Yes Yes Yes V + V Yes blocked Yes Carroll et al., 2012 High dose cocaine in mice and VEC + VAC combinations Effect on locomotor behavior 100 mg/kg cocaine 120 mg/kg, divided (60) 10 min apart CocH + VAC (AB) > VAC, CocH, SAL and Control in reducing locomotor behavior Carroll et al., 2012 VEC + VAC effects on cocaine (0.4 mg/kg) self-administration during 2-hr sessions
Load more

Recommended publications
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Anti-Inflammatory Effects of Amantadine and Memantine
    Journal of Personalized Medicine Communication Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1 , Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, E-28500 Madrid, Spain; [email protected] 2 University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, E-10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected]; Tel.: +34-636968395 Received: 2 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: We have reviewed current data on the anti-inflammatory effects of amantadine and memantine in clinical and in vivo models of inflammation, and we propose that these effects have potential interest for the treatment of the SARS-CoV-2 infection (COVID-19 disease). To that end, we performed a literature search using the PubMed Database from 1966 up to October 31 2020, crossing the terms “amantadine” and “memantine” with “inflammation” and “anti-inflammatory”. Amantadine and/or memantine have shown anti-inflammatory effects in chronic hepatitis C, in neuroinflammation induced by sepsis and by lipopolysaccharides, experimental models of multiple sclerosis, spinal cord injury, and respiratory diseases. Since the inflammatory response is one of the main pathogenetic mechanisms in the progression of the SARS-CoV-2 infection, anti-inflammatory effects of amantadine and memantine could be hypothetically useful in the treatment of this condition. This potential utility deserves further research. Keywords: amantadine; memantine; anti-inflammatory effects; SARS-Cov-2; COVID-19; therapy 1.
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels
    Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels by Shababa Tanzeel Masoud A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Pharmacology and Toxicology University of Toronto © Copyright by Shababa Tanzeel Masoud 2017 Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels Shababa Tanzeel Masoud Doctor of Philosophy Department of Pharmacology and Toxicology University of Toronto 2017 Abstract Dopamine is a key neurotransmitter that regulates motor coordination and dysfunction of the dopamine system gives rise to Parkinson’s disease. Nigrostriatal dopamine neurons are vulnerable to various genetic and environmental insults, suggesting that these cells are inherently at-risk. A cell-specific risk factor for these neurons is the neurotransmitter, dopamine itself. If intracellular dopamine is not appropriately sequestered into vesicles, it can accumulate in the cytosol. Cytosolic dopamine is highly reactive and can trigger oxidative stress, leading to cellular toxicity. Cytosolic dopamine levels are modulated by the plasma membrane dopamine transporter (DAT) that takes up dopamine from the extracellular space, and the vesicular monoamine transporter 2 (VMAT2) that stores dopamine into vesicles. In this thesis, we altered DAT and VMAT2 levels to investigate the detrimental consequences of potentially amplifying cytosolic dopamine in transgenic mice. Project 1 focused on selective over-expression of DAT in dopaminergic cells of transgenic mice (DAT-tg). DAT-tg mice displayed phenotypes of dopaminergic damage: increased dopamine-specific oxidative stress, L-DOPA-reversible fine motor deficits and enhanced sensitivity to toxicant insult, suggesting that increasing DAT- mediated dopamine uptake is detrimental for dopamine cells.
    [Show full text]
  • Lega Italiana Per La Lotta Contro La Malattia Di Parkinson Le Sindromi Extrapiramidali E Le Demenze
    LIMPE lega italiana per la lotta contro la malattia di parkinson le sindromi extrapiramidali e le demenze Web site: http://www.parkinson-limpe.it/ XXIX National Congress Lecce 23–25 October 2002 Parkinson Parkinsonism Dementia: from Biotechnology to Medical Management SELECTED SHORT PAPERS Scientific Committee Bruno Bergamasco, Giovanni U. Corsini, Mario Manfredi, Stefano Ruggieri, Pierfranco Spano Secretariat LIMPE Viale dell’Università 30, 00185 Roma Tel. and Fax: +39-06-4455618 E-mail: [email protected] Neurol Sci (2003) 24:149–150 DOI 10.1007/s10072-003-0103-5 123I-Ioflupane/SPECT binding to to the dopamine transporter (DAT) may be better suited and provide more-accurate estimation of degeneration. Several striatal dopamine transporter (DAT) tracers that bind to DAT and utilize SPECT are available; uptake in patients with Parkinson’s they are all cocaine derivatives. The most widely used are disease, multiple system atrophy, and [123I]β-CIT and 123I-Ioflupane ([123I]FP-CIT) [3, 4]. The main advantage of 123I-Ioflupane is that a steady state allow- progressive supranuclear palsy ing SPECT imaging is reached 3 h after a single bolus injec- 1 2 1 tion of the radioligand, compared with the 18–24 h required A. Antonini (౧) • R. Benti • R. De Notaris 1 1 1 for [123I]β-CIT. Therefore DAT imaging with 123I-Ioflupane S. Tesei • A. Zecchinelli • G. Sacilotto 1 1 1 1 can be completed the same day. N. Meucci • M. Canesi • C. Mariani • G. Pezzoli 123 P. Gerundini2 Several studies have demonstrated the usefulness of I- 1 Centro per la malattia di Parkinson, Dipartimento di Ioflupane SPECT imaging in the diagnosis of parkinsonism.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • Selective Knockdown of TASK3 Potassium Channel in Monoamine
    Manuscript Click here to download Manuscript Fullana et al - TASK3.docx 1 Research Article – Molecular Neurobiology 2 3 Selective Knockdown of TASK3 Potassium Channel in Monoamine 4 Neurons: A New Therapeutic Approach for Depression 5 M Neus Fullana1,2,3*, Albert Ferrés-Coy1,2,3*, Jorge E Ortega3,4, Esther Ruiz-Bronchal1,2,3, Verónica 6 Paz1,2,3, J Javier Meana3,4, Francesc Artigas1,2,3 and Analia Bortolozzi1,2,3 7 8 1Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain 9 2Department of Neurochemistry and Neuropharmacology, IIBB-CSIC (Consejo Superior de 10 Investigaciones Científicas), Barcelona, Spain. 11 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), ISCIII, Madrid, Spain. 12 4Department of Pharmacology, University of Basque Country UPV/EHU and BioCruces Health 13 Research Institute, Bizkaia, Spain 14 15 NF* and AF-C* contributed equally to this work. 16 For correspondence: Analia Bortolozzi, Department of Neurochemistry and Neuropharmacology 17 (IIBB-CSIC), Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Rosello 161, 18 Barcelona 08036, Spain. Tel: +34 93638313 Fax: +34 933638301 E-mail: 19 [email protected] 20 21 22 23 Running title: Intranasal delivery of conjugated TASK3-siRNA 24 25 26 1 Abstract 2 Current pharmacological treatments for major depressive disorder (MDD) are severely compromised 3 by both slow action and limited efficacy. RNAi strategies have been used to evoke antidepressant-like 4 effects faster than classical drugs. Using small interfering RNA (siRNA), we herein show that TASK3 5 potassium channel knockdown in monoamine neurons induces antidepressant-like responses in mice.
    [Show full text]
  • Positron Emission Tomography Studies of Potential Mechanisms Underlying Phencyclidine-Induced Alterations in Striatal Dopamine
    Neuropsychopharmacology (2003) 28, 2192–2198 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Positron Emission Tomography Studies of Potential Mechanisms Underlying Phencyclidine-Induced Alterations in Striatal Dopamine ,1,2 2 1,2 Wynne K Schiffer* , Jean Logan and Stephen L Dewey 1SUNY Stony Brook, Department of Neurobiology and Behavior, Stony Brook, NY, USA; 2Brookhaven National Laboratory, Chemistry Department, Upton, NY, USA 11 Positron emission tomography (PET), in combination with C-raclopride, was used to examine the effects of phencyclidine (PCP) on dopamine (DA) in the primate striatum. In addition, we explored the hypotheses that GABAergic pathways as well as molecular targets beyond the N-methyl-D-aspartate (NMDA) receptor complex (ie dopamine transporter proteins, DAT) contribute to PCP’s effects. In 11 the first series of experiments, C-raclopride was administered at baseline and 30 min following intravenous PCP administration. In the second series of studies, g-vinyl GABA (GVG) was used to assess whether enhanced GABAergic tone altered NMDA antagonist- induced changes in DA. Animals received an initial PET scan followed by pretreatment with GVG (300 mg/kg), then PCP 30 min prior to 11 a second scan. Finally, we explored the possible contributions of DAT blockade to PCP-induced increases in DA. By examining C- cocaine binding a paradigm in which PCP was coadministered with the radiotracer, we assessed the direct competition between these 11 two compounds for the DAT. At 0.1, 0.5, and 1.0 mg/kg, PCP decreased C-raclopride binding by 2.1, 14.9 7 2.2 and 8.18 7 1.1%, 11 respectively.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,469,601 B2 Vacher Et Al
    USOO94.69601 B2 (12) United States Patent (10) Patent No.: US 9,469,601 B2 Vacher et al. (45) Date of Patent: Oct. 18, 2016 (54) AMINOCYCLOBUTANE DERIVATIVES, FOREIGN PATENT DOCUMENTS METHOD FOR PREPARING SAME AND THE EP 0 747 348 A1 12/1996 USE THEREOF AS DRUGS EP O747348 A1 * 12, 1996 ............. CO7B 57/OO WO WO 98.07447 A1 2, 1998 (71) Applicant: PIERRE FABRE MEDICAMENT, WO WO 99.12537 A1 3, 1999 Boulogne-Billancourt (FR) WO WO 99.52848 A1 10, 1999 WO WOOOO3716 A1 1, 2000 WO WOOO, 51607 A1 9, 2000 (72) Inventors: Bernard Vacher, Castres (FR); Elodie WO WO 03/06165.6 A1 T 2003 Blanc, Semalens (FR); Ronan WO WO O3,063797 A2 8, 2003 Depoortere, Castres (FR) WO WO 2006/081179 A1 8, 2006 WO WO 2008/092.955 A1 8, 2008 WO WO 2009/O29618 A1 3, 2009 (73) Assignee: PIERRE FABRE MEDICAMENT, WO WO 2009/06961.0 A1 6, 2009 Boulogne-Billancourt (FR) WO WO 2009/092324 A1 T 2009 WO WO 2010/036937 A1 4/2010 (*) Notice: Subject to any disclaimer, the term of this WO WO 2010/037533 A1 4, 2010 patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 14/649,448 Aarts et al., “Novel Treatment of Excitotoxicity: Targeted Disrup (22) PCT Filed: Dec. 4, 2013 tion of Intracellular Signalling from Glutamate Receptors,” Bio chemical Pharmacology, vol. 66, 2003, pp. 877-886. (86). PCT No.: PCT/EP2013/075481 (Continued) S 371 (c)(1), (2) Date: Jun.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Dexmethylphenidate
    MICROMEDEX® Healthcare Series : Document Page 1 of 31 Case 3:09-cv-00080-TMB Document 78-23 Filed 03/24/2010 Page 1 of 105 DRUGDEX® Evaluations DEXMETHYLPHENIDATE 0.0 Overview 1) Class a) This drug is a member of the following class(es): Amphetamine Related CNS Stimulant 2) Dosing Information a) Dexmethylphenidate Hydrochloride 1) Adult a) Attention deficit hyperactivity disorder 1) extended-release: methylphenidate-naive patients, initial 10 mg ORALLY daily in the morning; adjust dose weekly in 10 mg increments; MAX 20 mg/day 2) extended-release: patients currently using methylphenidate, one-half the total daily dose of racemic methylphenidate; patients currently using dexmethylphenidate immediate-release may be switched to the same daily dose of dexmethylphenidate extended-release; MAX 20 mg/day 2) Pediatric a) safety and efficacy not established in patients under 6 years of age 1) Attention deficit hyperactivity disorder a) immediate-release (ages 6 years and older): methylphenidate-naive patients, initial 2.5 mg ORALLY twice daily; adjust dose weekly in 2.5 to 5 mg increments; MAX 20 mg/day (10 mg twice a day) b) immediate-release (ages 6 years and older): patients currently using methylphenidate, one-half the dose of racemic methylphenidate; MAX 20 mg/day (10 mg twice a day) c) extended-release (ages 6 years and older): methylphenidate-naive patients, initial 5 mg ORALLY in the morning; adjust dose weekly in 5 mg increments; MAX 20 mg/day(Prod Info FOCALIN XR(R) extended-release oral capsules, 2008) d) extended-release (ages 6 years
    [Show full text]